Home >NewS >Temozolomide Mechanism of Action (CAS No.85622-93-1): A Comprehensive Guide
Temozolomide Mechanism of Action (CAS No.85622-93-1): A Comprehensive Guide
Temozolomide Mechanism of Action

Temozolomide, identified by its CAS No. 85622-93-1, is a chemotherapy medication widely used in the treatment of certain brain tumors, most notably glioblastoma multiforme. Understanding the mechanism of action of temozolomide is crucial to appreciate how it combats cancer cells and why it is a cornerstone in the management of brain tumors. In this comprehensive guide, we will explore the intricate details of temozolomide's mechanism of action, its indications, dosing, potential side effects, and its role in the fight against cancer.

Introduction to Temozolomide:

Temozolomide is an oral alkylating agent and an imidazotetrazine derivative. It was developed as a prodrug, meaning that it is an inactive compound that undergoes chemical transformation within the body to become active. Temozolomide is particularly effective against brain tumors due to its ability to penetrate the blood-brain barrier, which is a protective barrier that surrounds the brain and spinal cord and limits the entry of many drugs and foreign substances.

Indications for Temozolomide Use:

Temozolomide is primarily indicated for the treatment of specific types of brain tumors, including:

  1. Glioblastoma Multiforme (GBM): GBM is the most aggressive and common type of primary brain tumor in adults. Temozolomide is a standard part of the treatment regimen for GBM.

  2. Anaplastic Astrocytoma: Temozolomide is also used in the treatment of anaplastic astrocytoma, another type of malignant brain tumor.

  3. Metastatic Melanoma: In some cases, temozolomide may be used to treat metastatic melanoma, a type of skin cancer, when it has spread to the brain.

Mechanism of Action:

The mechanism of action of temozolomide is both complex and highly effective in combating cancer cells. It involves several key steps:

  1. Prodrug Activation: Temozolomide is administered orally and is absorbed into the bloodstream from the gastrointestinal tract. Once in the body, it spontaneously converts to its active form at physiological pH. This conversion is essential for the drug's anti-cancer properties.

  2. DNA Alkylation: The active form of temozolomide can cross the blood-brain barrier and penetrate tumor tissue. Inside cancer cells, it chemically modifies DNA by adding alkyl groups to the DNA molecule. This alkylation damages the DNA structure, leading to breaks in the DNA strands.

  3. Methylating O6-Guanine Residue: Temozolomide primarily methylates the O6 position of guanine bases in DNA. This modification interferes with DNA replication and repair processes. Specifically, it creates mismatches during DNA replication, causing the incorporation of incorrect nucleotides.

  4. Activation of DNA Repair Mechanisms: Cells have mechanisms to repair damaged DNA. In response to temozolomide-induced DNA damage, cells activate their repair machinery. However, the O6-methylguanine lesion is particularly challenging for the repair systems to fix, resulting in the persistence of DNA damage.

  5. Cytotoxic Effect: Accumulation of unrepaired DNA damage is lethal to cancer cells. When these cells attempt to divide and replicate their DNA, the damaged DNA leads to errors, ultimately triggering cell death or apoptosis.

The specificity of temozolomide's action against cancer cells lies in the fact that rapidly dividing tumor cells are more susceptible to DNA damage and less capable of repairing it compared to normal, healthy cells.

Dosing and Administration:

Temozolomide is typically administered orally in the form of capsules or tablets. The dosing regimen and duration of treatment depend on the specific type and stage of cancer being treated. The dosage is often calculated based on body surface area to ensure optimal effectiveness and minimize side effects.

For patients with glioblastoma multiforme (GBM), the standard dosing schedule often involves:

  • An initial phase of daily temozolomide taken in combination with radiation therapy.
  • After the initial phase, there is typically a rest period.
  • Following the rest period, maintenance therapy with temozolomide continues with cycles of daily dosing for five days, followed by a 23-day rest period.
  • This cycle may be repeated for several months, depending on the patient's response and tolerability.

The dosing regimen for other indications may vary, and it is crucial for patients to adhere to the prescribed schedule as directed by their healthcare provider.

Side Effects of Temozolomide:

Temozolomide, like many chemotherapy medications, can cause side effects. The severity and presence of side effects can vary from person to person. Common side effects may include:

  1. Nausea and Vomiting: These symptoms can often be managed with antiemetic medications prescribed by a healthcare provider.

  2. Fatigue: Cancer-related fatigue is a common side effect of chemotherapy and may persist throughout treatment.

  3. Bone Marrow Suppression: Temozolomide can suppress the bone marrow's ability to produce blood cells, leading to an increased risk of anemia, leukopenia (low white blood cell count), and thrombocytopenia (low platelet count).

  4. Infections: A weakened immune system due to bone marrow suppression can increase susceptibility to infections. Patients should report any signs of infection to their healthcare provider.

  5. Headache: Some individuals may experience headaches as a side effect of temozolomide.

  6. Hair Loss: Temporary hair loss (alopecia) is possible with temozolomide treatment, but hair typically grows back after treatment is completed.

  7. Skin Rash: Skin reactions, including rashes, can occur but are usually mild.

  8. Liver Function Changes: Temozolomide can affect liver function, and liver enzymes are typically monitored during treatment.

  9. Digestive Issues: Diarrhea and constipation are possible side effects.

It's important for patients to communicate any side effects or concerns with their healthcare provider, as many side effects can be managed with supportive care or adjustments to the treatment plan.


Temozolomide (CAS No. 85622-93-1) is a vital component of cancer treatment, particularly in the management of aggressive brain tumors like glioblastoma multiforme. Its mechanism of action, which involves DNA alkylation and the induction of unrepaired DNA damage in cancer cells, makes it highly effective in targeting rapidly dividing cells. While temozolomide can cause side effects, its benefits in shrinking or controlling tumor growth and extending the lives of individuals with brain cancer are substantial. The decision to use temozolomide and the specific treatment regimen should always be made in consultation with a healthcare provider, taking into account the individual's medical condition, cancer type, and overall health. Through ongoing research and advancements in cancer treatment, temozolomide continues to play a critical role in the fight against cancer.

Have Questions about Arshine Pharma?
Our professional sales team are waiting for your consultation.


Sign up to receive our weekly newsletter